The specter of generic competition has repeatedly loomed around copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the future of connected pharmaceutical ventures. While first times saw impressive profits, the exclusivity lapse has opened the door for cheaper substitutes, possibly lowering profitability and presenting a real danger